Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Forecasted to Earn FY2026 Earnings of $7.64 Per Share

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) – Investment analysts at Piper Sandler issued their FY2026 earnings per share estimates for shares of Mirum Pharmaceuticals in a research note issued on Tuesday, January 11th. Piper Sandler analyst Y. Rahimi anticipates that the company will post earnings of $7.64 per share for the year.

MIRM has been the subject of a number of other research reports. SVB Leerink upped their price objective on shares of Mirum Pharmaceuticals from $32.00 to $41.00 and gave the stock an “outperform” rating in a research report on Thursday, September 30th. JPMorgan Chase & Co. began coverage on shares of Mirum Pharmaceuticals in a research report on Monday, September 20th. They issued an “overweight” rating and a $30.00 price objective for the company. Zacks Investment Research upgraded shares of Mirum Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, November 16th. HC Wainwright upped their price objective on shares of Mirum Pharmaceuticals from $51.00 to $64.00 and gave the stock a “buy” rating in a research report on Thursday, September 30th. Finally, Raymond James upped their price objective on shares of Mirum Pharmaceuticals from $69.00 to $70.00 and gave the stock a “strong-buy” rating in a research report on Wednesday. One investment analyst has rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Mirum Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $43.50.

NASDAQ:MIRM opened at $18.74 on Thursday. Mirum Pharmaceuticals has a one year low of $12.82 and a one year high of $22.14. The firm has a market cap of $574.16 million, a price-to-earnings ratio of -3.07 and a beta of 1.80. The firm’s fifty day moving average is $15.23 and its two-hundred day moving average is $15.98.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its quarterly earnings results on Monday, November 15th. The company reported ($1.55) EPS for the quarter, beating the consensus estimate of ($1.63) by $0.08. The business had revenue of $5.00 million during the quarter, compared to analysts’ expectations of $5.00 million. During the same period in the previous year, the company posted ($0.86) earnings per share.

In related news, CEO Christopher Peetz purchased 7,000 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Wednesday, November 24th. The stock was purchased at an average price of $14.40 per share, for a total transaction of $100,800.00. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In the last 90 days, insiders have purchased 8,450 shares of company stock valued at $121,305. Insiders own 62.50% of the company’s stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in MIRM. BVF Inc. IL acquired a new position in shares of Mirum Pharmaceuticals during the 3rd quarter worth about $8,684,000. BioImpact Capital LLC purchased a new stake in Mirum Pharmaceuticals during the 3rd quarter valued at about $6,146,000. AXA S.A. grew its stake in Mirum Pharmaceuticals by 28.8% during the 3rd quarter. AXA S.A. now owns 852,172 shares of the company’s stock valued at $16,975,000 after acquiring an additional 190,580 shares in the last quarter. Point72 Asset Management L.P. grew its stake in Mirum Pharmaceuticals by 668.1% during the 3rd quarter. Point72 Asset Management L.P. now owns 144,400 shares of the company’s stock valued at $2,876,000 after acquiring an additional 125,600 shares in the last quarter. Finally, Millennium Management LLC grew its stake in Mirum Pharmaceuticals by 194.8% during the 3rd quarter. Millennium Management LLC now owns 132,586 shares of the company’s stock valued at $2,641,000 after acquiring an additional 87,615 shares in the last quarter. Hedge funds and other institutional investors own 78.02% of the company’s stock.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a biopharmaceutical company. The firm focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its product candidates include Maralixibat and Volixibat. The company was founded by Niall O’Donnel, Michael Grey and Christopher Peetz on May 7, 2018 and is headquartered in Foster City, CA.

Read More: Trading Options- What is a Strangle?

Earnings History and Estimates for Mirum Pharmaceuticals (NASDAQ:MIRM)

Receive News & Ratings for Mirum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.